Mamoun Alhamadsheh, B.Pharm., Ph.D.
Department of Pharmaceutics and Medicinal Chemistry
Phone: (209) 946-3164
At Pacific Since:
PhD., 2004, University of Toledo, Toledo, OH
B.Pharm., 1999, Jordan University of Science and Technology, Jordan
Stanford University, 2008-2011
Portland State University, 2004-2007
• Protein-protein interactions
• Amyloid beta aggregation in Alzheimer's disease
• Transthyretin Amyloidosis
Our laboratory employs an interdisciplinary approach to study protein-protein interactions (PPIs), combining synthetic organic chemistry with biochemistry and molecular biology. We are interested in developing small molecules that can be used to probe or inhibit PPIs. These small molecules would be used to understand the structure and function of multi-protein complexes as well as to develop new leads for drug discovery. Due to the urgent need for new drugs, we are particularly interested in developing chemical tools and therapeutic agents for protein aggregation (a type of PPIs) diseases such as Alzheimer's disease and Transthyretin Amyloidosis.
Mamoun Alhamadsheh had his article "Potent Kinetic Stabilizers That Prevent Transthyretin-Mediated Cardiomyocyte Proteotoxicity" published and featured on the cover in Science Translational Medicine magazine. It was also mentioned in Chemical & Engineering News, published by the American Chemical Society, and The Alzheimer Research Forum.